Failure to bispecific-antibody therapy is associated with a short survival in highly pre-treated patients with aggressive B-Cell Lymphomas

Curr Res Transl Med. 2023 Apr-Jun;71(2):103388. doi: 10.1016/j.retram.2023.103388. Epub 2023 Mar 26.

Authors

Kohar Kevork¹, Melanie Gouin¹, Valentin Letailleur¹, Patrice Chevallier¹, Cyrille Touzeau¹, Thomas Gastinne¹, Bénédicte Piron¹, Benoît Tessoulin²

Affiliations

¹ Nantes University Hospital, CRCI2NA, 1 Place Alexis Ricordeau, Nantes 44093, France.
² Nantes University Hospital, CRCI2NA, 1 Place Alexis Ricordeau, Nantes 44093, France. Electronic address: [email protected].

PMID: 37099834
DOI: 10.1016/j.retram.2023.103388

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Bispecific* / therapeutic use
Humans
Lymphoma, B-Cell* / drug therapy

Substances

Antibodies, Bispecific